The implications of alternative pre-mRNA splicing in cell signal transduction

참고문헌 (165)

1. Pan, Q., "Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing", Nat. Genet, 40, pp.1413~1415 (2008)
2. Antebi, Y. E., "An operational view of intercellular signaling pathways", Curr. Opin. Syst. Biol, 1, pp.16~24 (2017)
3. Choi, S., "RBFOX2-regulated TEAD1 alternative splicing plays a pivotal role in Hippo-YAP signaling", Nucleic Acids Res, 50, pp.8658~8673 (2022)
4. Yuan, Y., "Characterization of Sin1 Isoforms Reveals an mTORDependent and Independent Function of Sin1gamma", PLoS One, 10, pp.e0135017~ (2015)
5. Aitken, A., "Post-translational modification of 14-3-3 isoforms and regulation of cellular function", Semin. Cell Dev. Biol, 22, pp.673~680 (2011)
6. Chan, I. H., "Isoform-specific transcriptional activity of overlapping target genes that respond to thyroid hormone receptors alpha1 and beta1", Mol. Endocrinol, 23, pp.1758~1775 (2009)
7. Moon, H., "Effects of PTCs on nonsense-mediated mRNA decay are dependent on PTC location", Oncol. Lett, 13, pp.1944~1948 (2017)
8. Hoskins, A. A., "Ordered and dynamic assembly of single spliceosomes", Science, 331, pp.1289~1295 (2011)
9. Will, C. L., "Spliceosome structure and function", Cold Spring Harb. Perspect. Biol, 3, pp.a003707~ (2011)
10. Faustino, N. A., "Pre-mRNA splicing and human disease", Genes Dev, 17, pp.419~437 (2003)
11. Bonnal, S. C., "Roles and mechanisms of alternative splicing in cancer-implications for care", Nat. Rev. Clin. Oncol, 17, pp.457~474 (2020)
12. Zhang, Y., "Alternative splicing and cancer : A systematic review", Signal Transduct. Target. Ther, 6, pp.78~ (2021)
13. Matlin, A. J., "Understanding alternative splicing : Towards a cellular code", Nat. Rev. Mol. Cell. Biol, 6, pp.386~398 (2005)
14. Shenasa, H., "Allosteric regulation of U1 snRNP by splicing regulatory proteins controls spliceosomal assembly", RNA, 26, pp.1389~1399 (2020)
15. Fu, X. D., "The superfamily of arginine", serine-rich splicing factors, 1995, pp.1, 663~680
16. Long, J. C., "The SR protein family of splicing factors: Master regulators of gene expression", Biochem. J, 417, pp.15~27 (2009)
17. Lee, Y., "Mechanisms and regulation of alternative Pre-mRNA splicing", Annu. Rev. Biochem, 84, pp.291~323 (2015)
18. Caceres, J. F., "Alternative splicing : Multiple control mechanisms and involvement in human disease", Trends Genet, 18, pp.186~193 (2002)
19. Wang, Z., "General and specific functions of exonic splicing silencers in splicing control", Mol. Cell, 23, pp.61~70 (2006)
20. Busch, A, "Evolution of SR protein and hnRNP splicing regulatory factors", Wiley Interdiscip. Rev. RNA, 3, pp.1~12 (2012)
21. Rothrock, C. R., "HnRNP L represses exon splicing via a regulated exonic splicing silencer", EMBO J, 24, pp.2792~2802 (2005)
22. Zhou, X., "Transcriptome analysis of alternative splicing events regulated by SRSF10 reveals position-dependent splicing modulation", Nucleic Acids Res, 42, pp.4019~4030 (2014)
23. Mayeda, A., "Function of conserved domains of hnRNP A1 and other hnRNP A", B proteins, 1994, pp.13, 5483~5495
24. Mayeda, A., "Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2", Cell, 68, pp.365~375 (1992)
25. Fu, X. D., "Context-dependent control of alternative splicing by RNAbinding proteins", Nat. Rev. Genet, 15, pp.689~701 (2014)
26. Kim, E., "Different levels of alternative splicing among eukaryotes", Nucleic Acids Res, 35, pp.125~131 (2007)
27. Briscoe, J., "The mechanisms of Hedgehog signalling and its roles in development and disease", Nat. Rev. Mol. Cell Biol, 14, pp.416~429 (2013)
28. Gupta, S., "Targeting the Hedgehog pathway in cancer", Ther. Adv. Med. Oncol, 2, pp.237~250 (2010)
29. Carballo, G. B., "A highlight on Sonic hedgehog pathway", Cell Commun. Signal, 16, pp.11~ (2018)
30. Skoda, A. M., "The role of the Hedgehog signaling pathway in cancer : A comprehensive review", Bosn. J. Basic Med. Sci, 18, pp.8~20 (2018)
31. Jeng, K. S., "Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma", Oncol. Lett, 18, pp.4377~4384 (2019)
32. Kotulak-Chrzaszcz, A., "Sonic Hedgehog signaling pathway in gynecological and genitourinary cancer (Review)", Int. J. Mol. Med, 47, pp.106~ (2021)
33. Yang, C., "The role of sonic hedgehog pathway in the development of the central nervous system and aging-related neurodegenerative diseases", Front. Mol. Biosci, 8, pp.711710~ (2021)
34. Wu, F., "Hedgehog signaling : From basic biology to cancer therapy", Cell Chem. Biol, 24, pp.252~280 (2017)
35. Palaniswamy, R., "Genetic variations regulate alternative splicing in the 5’ untranslated regions of the mouse glioma-associated oncogene 1, Gli1", BMC Mol. Biol, 11, pp.32~ (2010)
36. Shimokawa, T., "A novel first exon of the Patched1 gene is upregulated by Hedgehog signaling resulting in a protein with pathway inhibitory functions", FEBS Lett, 578, pp.157~162 (2004)
37. Agren, M., "Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site", Gene, 330, pp.101~114 (2004)
38. Kogerman, P., "Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein", Oncogene, 21, pp.6007~6016 (2002)
39. Shimokawa, T., "Distinct roles of first exon variants of the tumor-suppressor Patched1 in Hedgehog signaling", Oncogene, 26, pp.4889~4896 (2007)
40. Nagao, K., "Detecting tissue-specific alternative splicing and diseaseassociated aberrant splicing of the PTCH gene with exon junction microarrays", Hum. Mol. Genet, 14, pp.3379~3388 (2005)
41. Rahnama, F., "Distinct roles of PTCH2 splice variants in Hedgehog signalling", Biochem. J, 378, pp.325~334 (2004)
42. Wang, X. Q., "Post-transcriptional regulation of the gli1 oncogene by the expression of alternative 5’ untranslated regions", J. Biol. Chem, 276, pp.1311~1316 (2001)
43. Zaphiropoulos, P. G., "Genetic variations and alternative splicing : The Glioma associated oncogene 1, GLI1", Front. Genet, 3, pp.119~ (2012)
44. Shimokawa, T., "Novel human glioma-associated oncogene 1(GLI1)splice variants reveal distinct mechanisms in the terminal transduction of the hedgehog signal", J. Biol. Chem, 283, pp.14345~14354 (2008)
45. Lo, H. W., "A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion", Cancer Res, 69, pp.6790~6798 (2009)
46. Speek, M., "A potential role of alternative splicing in the regulation of the transcriptional activity of human GLI2 in gonadal tissues", BMC Mol. Biol, 7, pp.13~ (2006)
47. Tanimura, A., "Cloning of novel isoforms of the human Gli2oncogene and their activities to enhance tax-dependent transcription of the human T-cell leukemia virus type 1 genome", J. Virol, 72, pp.3958~3964 (1998)
48. Sadam, H., "GLI2 cell-specific activity is controlled at the level of transcription and RNA processing : Consequences to cancer metastasis", Biochim. Biophys. Acta, 1862, pp.46~55 (2016)
49. Siavriene, E., "Novel GLI3 variant causes Greig cephalopolysyndactyly syndrome in three generations of a Lithuanian family", Mol. Genet. Genomic Med, 7, pp.e878~ (2019)
50. Bournazos, A. M., "Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants", Genet. Med, 24, pp.130~145 (2022)
51. Harvey, K. F., "The Hippo pathway and human cancer", Nat. Rev. Cancer, 13, pp.246~257 (2013)
52. Ma, S., "The hippo pathway : Biology and pathophysiology", Annu. Rev. Biochem, 88, pp.577~604 (2019)
53. Meng, Z., "Mechanisms of Hippo pathway regulation", Genes Dev, 30, pp.1~17 (2016)
54. Harvey, K., "The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network", Nat. Rev. Cancer, 7, pp.182~191 (2007)
55. Misra, J. R., "The Hippo Signaling Network and Its Biological Functions", Annu. Rev. Genet, 52, pp.65~87 (2018)
56. Zhao, B., "Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control", Genes Dev, 21, pp.2747~2761 (2007)
57. Zhao, B., "A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)", Genes Dev, 24, pp.72~85 (2010)
58. Liu, C. Y., "The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase", J. Biol. Chem, 285, pp.37159~37169 (2010)
59. Gaffney, C. J., "Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene", Gene, 509, pp.215~222 (2012)
60. Finch-Edmondson, M. L., "Splice variant insertions in the C-terminus impairs YAP’s transactivation domain", Biochem. Biophys. Rep, 6, pp.24~31 (2016)
61. Das, S., "Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC", Cell Rep, 1, pp.110~117 (2012)
62. Qi, Y., "A splicing isoform of TEAD4 attenuates the Hippo-YAP signalling to inhibit tumour proliferation", Nat. Commun, 7, pp.ncomms11840~ (2016)
63. Bangru, S., "Alternative splicing rewires Hippo signaling pathway in hepatocytes to promote liver regeneration", Nat. Struct. Mol. Biol, 25, pp.928~939 (2018)
64. Hyun, J., "Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis", J. Clin. Invest, 130, pp.2129~2145 (2020)
65. Hyun, J., "Dysregulation of the ESRP2-NF2-YAP", TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease, 2021, pp.75, 623~633
66. Qureshy, Z., "Targeting the JAK", STAT pathway in solid tumors, 2020, pp.6, 27~
67. O’Shea, J. J., "The JAK-STAT pathway : Impact on human disease and therapeutic intervention", Annu. Rev. Med, 66, pp.311~328 (2015)
68. Morris, R., "The molecular details of cytokine signaling via the JAK", STAT pathway, 2018, pp.27, 1984~2009
69. Hu, X., "The JAK", STAT signaling pathway : from bench to clinic, 2021, pp.6, 402~
70. Ma, W., "JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms", PLoS One, 5, pp.e12165~ (2010)
71. Catarsi, P., "JAK2 exon 14 skipping in patients with primary myelofibrosis : A minor splice variant modulated by the JAK2-V617F allele burden", PLoS One, 10, pp.e0116636~ (2015)
72. Lai, K. S., "A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells", J. Biol. Chem, 270, pp.25028~25036 (1995)
73. Platt, C. D., "Janus kinase 3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site", J. Allergy Clin. Immunol, 140, pp.268~271 (2017)
74. Wu, K., "Isolation and expression analysis of STAT members from synechogobius hasta and their roles in leptin affecting lipid metabolism", Int. J. Mol. Sci, 17, pp.406~ (2016)
75. Song, H., "The role of stat1b in zebrafish hematopoiesis", Mech. Dev, 128, pp.442~456 (2011)
76. Wang, D., "A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosinephosphorylated Stat5", EMBO J, 19, pp.392~399 (2000)
77. Caldenhoven, E., "STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription", J. Biol. Chem, 271, pp.13221~13227 (1996)
78. Shuai, K., "A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma", Science, 261, pp.1744~1746 (1993)
79. Parrini, M., "The C-Terminal transactivation domain of STAT1 has a genespecific role in transactivation and cofactor recruitment", Front. Immunol, 9, pp.2879~ (2018)
80. Semper, C., "STAT1beta is not dominant negative and is capable of contributing to gamma interferon-dependent innate immunity", Mol. Cell. Biol, 34, pp.2235~2248 (2014)
81. Meissl, K., "STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity", Front. Immunol, 11, pp.2189~ (2020)
82. Vairo, D., "Severe impairment of IFN-gamma and IFN-alpha responses in cells of a patient with a novel STAT1 splicing mutation", Blood, 118, pp.1806~1817 (2011)
83. Maritano, D., "The STAT3 isoforms alpha and beta have unique and specific functions", Nat. Immunol, 5, pp.401~409 (2004)
84. Ng, I. H., "Cytokine-induced slowing of STAT3nuclear import; faster basal trafficking of the STAT3beta isoform", Traffic, 15, pp.946~960 (2014)
85. Turton, K. B., "Ratios of Four STAT3Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells", PLoS One, 10, pp.e0127243~ (2015)
86. Zheng, M., "A mix of S and DeltaS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture", Oncogenesis, 4, pp.e184~ (2016)
87. Hoey, T., "Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses", EMBO J, 22, pp.4237~4248 (2003)
88. Barnabei, L., "NF-kappaB : At the Borders of Autoimmunity and Inflammation", Front. Immunol, 12, pp.716469~ (2021)
89. Xia, L., "Role of the NFkappaB-signaling pathway in cancer", Onco. Targets Ther, 11, pp.2063~2073 (2018)
90. Hoesel, B., "The complexity of NF-kappaB signaling in inflammation and cancer", Mol. Cancer, 12, pp.86~ (2013)
91. Liu, T., "NF-kappaB signaling in inflammation", Signal Transduct. Target. Ther, 2, pp.17023~ (2017)
92. Zhang, Q., "30 Years of NF-kappaB : A Blossoming of Relevance to Human Pathobiology", Cell, 168, pp.37~57 (2017)
93. Taniguchi, K., "NF-kappaB, inflammation, immunity and cancer : coming of age", Nat. Rev. Immunol, 18, pp.309~324 (2018)
94. Albensi, B. C., "What Is Nuclear Factor Kappa B(NF-kappaB)Doing in and to the Mitochondrion?", Front. Cell Dev. Biol, 7, pp.154~ (2019)
95. Seitz, C., "A novel p75TNF receptor isoform mediating NFkappa B activation", J. Biol. Chem, 276, pp.19390~19395 (2001)
96. Haehnel, V., "Transcriptional regulation of the human toll-like receptor 2 gene in monocytes and macrophages", J. Immunol, 168, pp.5629~5637 (2002)
97. Chang, J. S., "Myobacterium tuberculosis induces selective up-regulation of TLRs in the mononuclear leukocytes of patients with active pulmonary tuberculosis", J. Immunol, 176, pp.3010~3018 (2006)
98. Hai, T., "An alternative splice product of IkappaB kinase(IKKgamma), IKKgamma-delta, differentially mediates cytokine and human T-cell leukemia virus type 1 tax-induced NF-kappaB activation", J. Virol, 80, pp.4227~4241 (2006)
99. Orstavik, K. H., "Novel splicing mutation in the NEMO(IKK-gamma)gene with severe immunodeficiency and heterogeneity of X-chromosome inactivation", Am. J. Med. Genet. A, 140, pp.31~39 (2006)
100. Willems, M., "IkappaBzeta: An emerging player in cancer", Oncotarget, 7, pp.66310~66322 (2016)
101. Yamazaki, S., "Stimulus-specific induction of a novel nuclear factor-kappaB regulator, IkappaB-zeta, via Toll", Interleukin-1receptor is mediated by mRNA stabilization, 2005, pp.280, 1678~1687
102. Motoyama, M., "Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein", J. Biol. Chem, 280, pp.7444~7451 (2005)
103. Phan, H. H., "CD14-dependent modulation of NF-kappaB alternative splicing in the lung after burn injury", Gene, 371, pp.121~129 (2006)
104. Song, J., "Novel Form of Alternative Splicing of NFKB1. Its Role in Polycythemia and Adaptation to High Altitude in Andean Aymara", Blood, 132, pp.2316~ (2018)
105. Li, J., "Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency", J. Exp. Med, 218, pp.e20210566~ (2021)
106. Leeman, J. R., "Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL", Oncogene, 27, pp.6770~6781 (2008)
107. Zhou, B., "Notch signaling pathway : architecture, disease, and therapeutics", Signal Transduct. Target. Ther, 7, pp.95~ (2022)
108. Shen, W., "Biological Significance of NOTCH Signaling Strength", Front. Cell Dev. Biol, 9, pp.652273~ (2021)
109. Adamia, S., "NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia(AML) : new potential targets in AML", Blood, 123, pp.2816~2825 (2014)
110. Hwang, I. S., "NOTCH2 missplicing can occur in relation to apoptosis", Blood, 126, pp.1731~1732 (2015)
111. Bianchi, S., "First deep intronic mutation in the NOTCH3 gene in a family with late-onset CADASIL", Neurobiol. Aging, 34, pp.9~12 (2013)
112. Jespersen, D. S., "Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis", Sci. Rep, 9, pp.335~ (2019)
113. Joutel, A., "Splice site mutation causing a seven amino acid Notch3 in-frame deletion in CADASIL", Neurology, 54, pp.1874~1875 (2000)
114. Aversa, R., "Alternative splicing in adhesion-and motility-related genes in breast cancer", Int. J. Mol. Sci, 17, pp.121~ (2016)
115. Welcker, M., "Fbw7", hCDC4 dimerization regulates its substrate interactions, 2007, pp.2, 7~
116. Grim, J. E., "Isoform-and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase", J. Cell. Biol, 181, pp.913~920 (2008)
117. Liu, Y., "Multiple novel alternative splicing forms of FBXW7alpha have a translational modulatory function and show specific alteration in human cancer", PLoS One, 7, pp.e49453~ (2012)
118. Sionov, R. V., "Differential regulation of FBXW7 isoforms by various stress stimuli", Cell Cycle, 12, pp.3547~3554 (2013)
119. Kim, K. K., "Rbfox3-regulated alternative splicing of Numb promotes neuronal differentiation during development", J. Cell. Biol, 200, pp.443~458 (2013)
120. Zong, F. Y., "The RNA-binding protein QKI suppresses cancer-associated aberrant splicing", PLoS Genet, 10, pp.e1004289~ (2014)
121. Zhang, T., "NOVA1-Mediated SORBS2 Isoform Promotes Colorectal Cancer Migration by Activating the Notch Pathway", Front. Cell Dev. Biol, 9, pp.673873~ (2021)
122. Akhurst, R. J., "Targeting the TGFbeta signalling pathway in disease", Nat. Rev. Drug Discov, 11, pp.790~811 (2012)
123. Massague, J., "TGFbeta signalling in context", Nat. Rev. Mol. Cell Biol, 13, pp.616~630 (2012)
124. Huang, F., "Regulation of TGF-beta receptor activity", Cell Biosci, 2, pp.9~ (2012)
125. Liu, S., "TGFbeta signaling : A complex role in tumorigenesis(Review)", Mol. Med. Rep, 17, pp.699~704 (2018)
126. Fujiwara, T., "Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma", Eur. J. Hum. Genet, 26, pp.1151~1158 (2018)
127. Chen, T., "An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder", Int. J. Cancer, 112, pp.420~425 (2004)
128. Rotzer, D., "Type III TGF-beta receptor-independent signalling of TGF-beta2via TbetaRII-B, an alternatively spliced TGF-beta type II receptor", EMBO J, 20, pp.480~490 (2001)
129. del Re, E., "In the absence of type III receptor, the transforming growth factor(TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2", J. Biol. Chem, 279, pp.22765~22772 (2004)
130. Yagi, K., "Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3", J. Biol. Chem, 274, pp.703~709 (1999)
131. Tao, S., "Alternative splicing of SMADs in differentiation and tissue homeostasis", Dev. Growth Differ, 52, pp.335~342 (2010)
132. Ueberham, U., "Smad2 isoforms are differentially expressed during mouse brain development and aging", Int. J. Dev. Neurosci, 27, pp.501~510 (2009)
133. Kjellman, C., "Identification and characterization of a human smad3 splicing variant lacking part of the linker region", Gene, 327, pp.141~152 (2004)
134. Nishita, M., "Smad8B, a Smad8 splice variant lacking the SSXS site that inhibits Smad8-mediated signalling", Genes Cells, 4, pp.583~591 (1999)
135. Liu, J., "Wnt", beta-catenin signalling : function, biological mechanisms, and therapeutic opportunities, 2022, pp.7, 3~
136. Azbazdar, Y., "Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer", Front. Cell Dev. Biol, 9, pp.631623~ (2021)
137. Patel, S., "Wnt Signaling and Its Significance Within the Tumor Microenvironment : Novel Therapeutic Insights", Front. Immunol, 10, pp.2872~ (2019)
138. Zhang, Y., "Targeting the Wnt", beta-catenin signaling pathway in cancer, 2020, pp.13, 165~
139. Rim, E. Y., "The Wnt Pathway : From Signaling Mechanisms to Synthetic Modulators", Annu. Rev. Biochem, 91, pp.571~598 (2022)
140. Charames, G. S., "A novel aberrant splice site mutation in the APC gene", J. Med. Genet, 39, pp.754~757 (2002)
141. Cheah, P. Y., "A novel indel in exon 9 of APC upregulates a ‘skip exon 9’isoform and causes very severe familial adenomatous polyposis", Eur. J. Hum. Genet, 22, pp.833~836 (2014)
142. Wanitsuwan, W., "A distinct APC pathogenic germline variant identified in a southern Thai family with familial adenomatous polyposis", BMC Med. Genomics, 14, pp.87~ (2021)
143. Disciglio, V., "APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome", Genes(Basel), 12, pp.353~ (2021)
144. Shafienia, S., "A novel splice-site mutation in the LRP5 gene causing Familial Exudative Vitreoretinopathy", Gene Reports, 21, pp.100801~ (2020)
145. Laine, C. M., "Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome(OPPG)", Eur. J. Hum. Genet, 19, pp.875~881 (2011)
146. Korvala, J., "Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity", BMC Med. Genet, 13, pp.26~ (2012)
147. Little, R. D., "A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait", Am. J. Hum. Genet, 70, pp.11~19 (2002)
148. Boyden, L. M., "High bone density due to a mutation in LDL-receptor-related protein 5", N. Engl. J. Med, 346, pp.1513~1521 (2002)
149. Roman-Gomez, J., "Transcriptional silencing of the Dickkopfs-3(Dkk-3)gene by CpG hypermethylation in acute lymphoblastic leukaemia", Br. J. Cancer, 91, pp.707~713 (2004)
150. Kobayashi, K., "Reduced expression of the REIC", Dkk-3 gene by promoterhypermethylation in human tumor cells, 2002, pp.282, 151~158
151. Kwok, J. B., "GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease", Ann. Neurol, 58, pp.829~839 (2005)
152. Wang, L., "Alternative splicing of the porcine glycogen synthase kinase 3beta(GSK-3beta)gene with differential expression patterns and regulatory functions", PLoS One, 7, pp.e40250~ (2012)
153. Patturajan, M., "DeltaNp63 induces beta-catenin nuclear accumulation and signaling", Cancer Cell, 1, pp.369~379 (2002)
154. Chakrabarti, R., "DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling", Nat. Cell Biol, 16, pp.1~13 (2014)
155. Brkic, S., "Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy", Leukemia, 35, pp.2875~2884 (2021)
156. Wolf, A., "JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells", JAKSTAT, 2, pp.e24574~ (2013)
157. Longhi, M. T., "PI3K-AKT, JAK2-STAT3 pathways and cell-cell contact regulate maspin subcellular localization", Cell Commun. Signal, 19, pp.86~ (2021)
158. Wang, J., "Feedback activation of STAT3 limits the response to PI3K", AKT, Oncogenesis, pp.2021, 10[DOI]
159. Vogt, P. K., "PI3K and STAT3 : A new alliance", Cancer Discov, 1, pp.481~486 (2011)
160. Liang, F., "The crosstalk between STAT3 and p53", RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug, PI3K, pp.AKT-mediated regulation of EMT and autophagy, Oncogenesis[DOI]
161. Amarasinghe, S. L., "Opportunities and challenges in long-read sequencing data analysis", Genome Biol, 21, pp.30~ (2020)
162. Tilgner, H., "Defining a personal, allelespecific, and single-molecule long-read transcriptome", Proc. Natl. Acad. Sci. USA, 111, pp.9869~9874 (2014)
163. Steijger, T., "Assessment of transcript reconstruction methods for RNA-seq", Nat. Methods, 10, pp.1177~1184 (2013)
164. Pollard, M. O., "Long reads : Their purpose and place", Hum. Mol. Genet, 27, pp.R234~R241 (2018)
165. Hu, Y., "LIQA : Long-read isoform quantification and analysis", Genome Biol, 22, pp.182~ (2021)

관련 논문AI추천